21-hydroxylase deficiency medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 53: Line 53:


===Adults management===
===Adults management===
 
21 hydroxylase deficiency should be managed as follows:<ref name="pmid2843311">{{cite journal| author=Horrocks PM, London DR| title=Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. | journal=Clin Endocrinol (Oxf) | year= 1987 | volume= 27 | issue= 6 | pages= 635-42 | pmid=2843311 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2843311  }}</ref><ref name="pmid27623069">{{cite journal| author=Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G| title=Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency. | journal=J Clin Endocrinol Metab | year= 2016 | volume= 101 | issue= 12 | pages= 4843-4850 | pmid=27623069 | doi=10.1210/jc.2016-2221 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27623069  }}</ref><ref name="pmid20823466">{{cite journal| author=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP et al.| title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2010 | volume= 95 | issue= 9 | pages= 4133-60 | pmid=20823466 | doi=10.1210/jc.2009-2631 | pmc=2936060 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20823466  }}</ref><ref name="pmid3060026">{{cite journal| author=Hughes IA| title=Management of congenital adrenal hyperplasia. | journal=Arch Dis Child | year= 1988 | volume= 63 | issue= 11 | pages= 1399-404 | pmid=3060026 | doi= | pmc=1779155 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3060026  }}</ref><ref name="pmid19258407">{{cite journal| author=Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M et al.| title=High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 5 | pages= 1665-70 | pmid=19258407 | doi=10.1210/jc.2008-1414 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19258407  }}</ref><ref name="pmid17090637">{{cite journal| author=Claahsen-van der Grinten HL, Otten BJ, Takahashi S, Meuleman EJ, Hulsbergen-van de Kaa C, Sweep FC et al.| title=Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. | journal=J Clin Endocrinol Metab | year= 2007 | volume= 92 | issue= 2 | pages= 612-5 | pmid=17090637 | doi=10.1210/jc.2006-1311 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17090637  }}</ref>]].<ref name="pmid19250265">{{cite journal| author=Casteràs A, De Silva P, Rumsby G, Conway GS| title=Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. | journal=Clin Endocrinol (Oxf) | year= 2009 | volume= 70 | issue= 6 | pages= 833-7 | pmid=19250265 | doi=10.1111/j.1365-2265.2009.03563.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19250265  }}</ref>
==== Treatment goals ====
==== Treatment goals ====
* Provide proper dosing of [[glucocorticoid]] and [[mineralocorticoid]].
* Provide proper dosing of [[glucocorticoid]] and [[mineralocorticoid]].
Line 59: Line 59:
====='''Glucocorticoids''' =====
====='''Glucocorticoids''' =====
* [[Glucocorticoids]] reduce the excess production of [[adrenal]] [[androgens]] and reduce the excessive secretion of both [[corticotropin-releasing hormone]] and  [[ACTH]].
* [[Glucocorticoids]] reduce the excess production of [[adrenal]] [[androgens]] and reduce the excessive secretion of both [[corticotropin-releasing hormone]] and  [[ACTH]].
* Preferred Regimen   
* Preferred Regimen   
** [[Hydrocortisone]] 15-30 mg/d divided into three doses.   
** [[Hydrocortisone]] 15-30 mg/d divided into three doses.   
* Alternative Regimen:
* Alternative Regimen:
** [[Dexamethasone]] a very potent and long-acting [[glucocorticoid]] effectively suppresses [[ACTH]] secretion but almost always causes the development of [[cushingoid appearance]] with chronic use.<ref name="pmid2843311">{{cite journal| author=Horrocks PM, London DR| title=Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. | journal=Clin Endocrinol (Oxf) | year= 1987 | volume= 27 | issue= 6 | pages= 635-42 | pmid=2843311 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2843311  }}</ref>
** [[Dexamethasone]] a very potent and long-acting [[glucocorticoid]] effectively suppresses [[ACTH]] secretion but almost always causes the development of [[cushingoid appearance]] with chronic use.
 
* Combination therapy, with typical doses of [[hydrocortisone]] to replace the [[cortisol]] deficiency during the day and a very small dose of a long-acting [[glucocorticoid]]. We suggest this approach when standard [[hydrocortisone]] regimens are ineffective.
* Combination therapy, with typical doses of [[hydrocortisone]] to replace the [[cortisol]] deficiency during the day and a very small dose of a long-acting [[glucocorticoid]]. We suggest this approach when standard [[hydrocortisone]] regimens are ineffective.
* '''Stress dosing''': patients with classic 21hydroxyalase deficiency should be provided stress dosing.<ref name="pmid27623069">{{cite journal| author=Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G| title=Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency. | journal=J Clin Endocrinol Metab | year= 2016 | volume= 101 | issue= 12 | pages= 4843-4850 | pmid=27623069 | doi=10.1210/jc.2016-2221 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27623069  }}</ref>
* '''Stress dosing''': patients with classic 21hydroxyalase deficiency should be provided stress dosing.
'''Mineralocorticoid replacement''' 
'''Mineralocorticoid replacement''' 
* [[Fludrocortisone Acetate|Fludrocortisone acetate]], in a dose sufficient to restore normal serum [[potassium]] concentrations and [[plasma renin activity]].<ref name="pmid20823466">{{cite journal| author=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP et al.| title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2010 | volume= 95 | issue= 9 | pages= 4133-60 | pmid=20823466 | doi=10.1210/jc.2009-2631 | pmc=2936060 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20823466  }}</ref>
* [[Fludrocortisone Acetate|Fludrocortisone acetate]], in a dose sufficient to restore normal serum [[potassium]] concentrations and [[plasma renin activity]].
* The usual adult dose of [[fludrocortisone]] is 0.1 to 0.2 mg/day.<ref name="pmid3060026">{{cite journal| author=Hughes IA| title=Management of congenital adrenal hyperplasia. | journal=Arch Dis Child | year= 1988 | volume= 63 | issue= 11 | pages= 1399-404 | pmid=3060026 | doi= | pmc=1779155 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3060026  }}</ref>
* The usual adult dose of [[fludrocortisone]] is 0.1 to 0.2 mg/day.
* Patients who are undertreated and in chronic poor control develop [[testicular]] [[Adrenal tumor|adrenal rest tumors.]]
* Patients who are undertreated and in chronic poor control develop [[testicular]] [[Adrenal tumor|adrenal rest tumors]].


===== '''Infertility in men''' =====
===== '''Infertility in men''' =====
*[[Sperm]] production is often impaired in untreated men due to defected [[spermatogenesis]] and [[leydig cells]] suppression.<ref name="pmid19258407">{{cite journal| author=Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M et al.| title=High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 5 | pages= 1665-70 | pmid=19258407 | doi=10.1210/jc.2008-1414 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19258407  }}</ref>
*[[Sperm]] production is often impaired in untreated men due to defected [[spermatogenesis]] and [[leydig cells]] suppression*Most of the patients have severe [[oligospermia]]. Moreover, Most of the untreated patients have [[Testicular tumor|testicular tumors]] that need surgical removal.
*Most of the patients have severe [[oligospermia]]. Moreover, Most of the untreated patients have [[Testicular tumor|testicular tumors]] that need surgical removal.
*An elevated [[FSH]] is a sensitive indicator for patients [[fertility]] condition but [[semen analysis]] is the specific test.
*An elevated [[FSH]] is a sensitive indicator for patients [[fertility]] condition but [[semen analysis]] is the specific test.<ref name="pmid17090637">{{cite journal| author=Claahsen-van der Grinten HL, Otten BJ, Takahashi S, Meuleman EJ, Hulsbergen-van de Kaa C, Sweep FC et al.| title=Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. | journal=J Clin Endocrinol Metab | year= 2007 | volume= 92 | issue= 2 | pages= 612-5 | pmid=17090637 | doi=10.1210/jc.2006-1311 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17090637  }}</ref>
 
===== '''Infertility in women''' =====
===== '''Infertility in women''' =====
* Lowering blood [[androgen]] levels helps women to control annoying [[Cosmetics|cosmetic]] symptoms such as [[acne]] and [[hirsutism]].
* Lowering blood [[androgen]] levels helps women to control annoying [[Cosmetics|cosmetic]] symptoms such as [[acne]] and [[hirsutism]].
* Similar to [[polycystic ovary syndrome]], 21 hydroxylase deficiency patients need [[oral contraceptive pills]] to regulate the [[menstrual cycle]] and induction of [[ovulation]].<ref name="pmid19250265">{{cite journal| author=Casteràs A, De Silva P, Rumsby G, Conway GS| title=Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. | journal=Clin Endocrinol (Oxf) | year= 2009 | volume= 70 | issue= 6 | pages= 833-7 | pmid=19250265 | doi=10.1111/j.1365-2265.2009.03563.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19250265  }}</ref>
* Similar to [[polycystic ovary syndrome]], 21 hydroxylase deficiency patients need [[oral contraceptive pills]] to regulate the [[menstrual cycle]] and induction of [[ovulation.
* Women need pregnancy should consult a [[surgeon]] to repair previous [[genital]] malformations.
* Women need pregnancy should consult a [[surgeon]] to repair previous [[genital]] malformations.
* [[Hydrocortisone]] doesn’t pass [[placenta]] so, it can be used safely during [[pregnancy]].
* [[Hydrocortisone]] doesn’t pass [[placenta]] so, it can be used safely during [[pregnancy]].

Revision as of 14:26, 2 August 2017

Congenital adrenal hyperplasia main page

21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 21-Hydroxylase Deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency medical therapy

CDC on 21-hydroxylase deficiency medical therapy

21-hydroxylase deficiency medical therapy in the news

Blogs on 21-hydroxylase deficiency medical therapy

Directions to Hospitals Treating 21-Hydroxylase Deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Mohammed Abdelwahed M.D[3]

Overview

Medical Therapy

Neonatal management

Medical therapy in 21 hydroxylase deficiency should be treated differently in prenatal, neonates, children and adults, as follows:[1][2][3][4]

Prenatal treatment

In the prenatal period virilization of female fetus begins early; therefore, early diagnosis and treatment are required as following:[4][5][2]

Neonatal treatment

21 hydroxylase deficiency therapy medications in the neonates are as following:[4]

Ambiguous genitalia 

Adrenal crisis

Children management

  • Mineralocorticoid replacement should be started in all children and often may be tapered after six months of age.

Adults management

21 hydroxylase deficiency should be managed as follows:[11][12][4][13][14][15]]].[16]

Treatment goals

Glucocorticoids 

Mineralocorticoid replacement 

Infertility in men
Infertility in women

References

  1. Merke DP, Bornstein SR (2005). "Congenital adrenal hyperplasia". Lancet. 365 (9477): 2125–36. doi:10.1016/S0140-6736(05)66736-0. PMID 15964450.
  2. 2.0 2.1 2.2 "Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology". J. Clin. Endocrinol. Metab. 87 (9): 4048–53. 2002. doi:10.1210/jc.2002-020611. PMID 12213842.
  3. Speiser PW (2001). "Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency". Endocrinol. Metab. Clin. North Am. 30 (1): 31–59, vi. PMID 11344938.
  4. 4.0 4.1 4.2 4.3 4.4 Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP; et al. (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.
  5. Bose KS, Sarma RH (1975). "Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution". Biochem Biophys Res Commun. 66 (4): 1173–9. PMID 22237438 2 22237438 Check |pmid= value (help).
  6. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP; et al. (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.
  7. Lajic S, Wedell A, Bui TH, Ritzén EM, Holst M (1998). "Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia". J Clin Endocrinol Metab. 83 (11): 3872–80. doi:10.1210/jcem.83.11.5233. PMID 9814461.
  8. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ; et al. (2007). "Maternal corticosteroid use and orofacial clefts". Am J Obstet Gynecol. 197 (6): 585.e1–7, discussion 683-4, e1–7. doi:10.1016/j.ajog.2007.05.046. PMID 18060943.
  9. Wallensteen L, Zimmermann M, Thomsen Sandberg M, Gezelius A, Nordenström A, Hirvikoski T; et al. (2016). "Sex-Dimorphic Effects of Prenatal Treatment With Dexamethasone". J Clin Endocrinol Metab. 101 (10): 3838–3846. doi:10.1210/jc.2016-1543. PMID 27482827.
  10. Khalife N, Glover V, Taanila A, Ebeling H, Järvelin MR, Rodriguez A (2013). "Prenatal glucocorticoid treatment and later mental health in children and adolescents". PLoS One. 8 (11): e81394. doi:10.1371/journal.pone.0081394. PMC 3838350. PMID 24278432.
  11. Horrocks PM, London DR (1987). "Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia". Clin Endocrinol (Oxf). 27 (6): 635–42. PMID 2843311.
  12. Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G (2016). "Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency". J Clin Endocrinol Metab. 101 (12): 4843–4850. doi:10.1210/jc.2016-2221. PMID 27623069.
  13. Hughes IA (1988). "Management of congenital adrenal hyperplasia". Arch Dis Child. 63 (11): 1399–404. PMC 1779155. PMID 3060026.
  14. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M; et al. (2009). "High prevalence of reduced fecundity in men with congenital adrenal hyperplasia". J Clin Endocrinol Metab. 94 (5): 1665–70. doi:10.1210/jc.2008-1414. PMID 19258407.
  15. Claahsen-van der Grinten HL, Otten BJ, Takahashi S, Meuleman EJ, Hulsbergen-van de Kaa C, Sweep FC; et al. (2007). "Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients". J Clin Endocrinol Metab. 92 (2): 612–5. doi:10.1210/jc.2006-1311. PMID 17090637.
  16. Casteràs A, De Silva P, Rumsby G, Conway GS (2009). "Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate". Clin Endocrinol (Oxf). 70 (6): 833–7. doi:10.1111/j.1365-2265.2009.03563.x. PMID 19250265.